glaucomaНациональный журнал ГлаукомаNational Journal glaucoma2078-41042311-6862Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”10.53432/2078-4104-2022-21-2-84-92glaucoma-388Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEW OF LITERATUREБета-адреноблокаторы: вопросы взаимодействия при местном и системном примененииBeta-blockers: issues of drug interactions in local and systemic deliveryМакогонС. И.MakogonI. S.

Макогон Светлана Ивановна - кандидат медицинских наук, доцент, заведующая курсом офтальмологии ФГБОУ ВО Алтайский ГМУ, заведующая взрослым офтальмологическим поликлиническим отделенем КГБУЗ Алтайская КОБ.

МЗ РФ, 656038, Барнаул, пр. Ленина, 40; 656002, Барнаул, ул. Советская, 8

Cand. Sci. (Med.), Associate Professor, Head of the Ophthalmology Curriculum Altai SMU, Head of the Adult Ophthalmological Polyclinic Department Altai ROH.

40 Lenina Ave., Barnaul, 656038; 8 Sovetskaya St., Barnaul, 656002

vvk_msi@mail.ruИвановаД. И.IvanovaD. I.

Ассистент курса офтальмологии.

МЗ РФ, 656038, Барнаул, пр. Ленина, 40

Assistant of the Ophthalmology Curriculum.

40 Lenina Ave., Barnaul, 656038

ОнищенкоА. Л.OnishchenkoA. L.

Доктор медицинских наук, профессор, заведующий кафедрой офтальмологии.

654005, Новокузнецк, пр. Строителей, 5

Dr. Sci. (Med.), Professor, Head of the Academic Department of Ophthalmology.

5 Stroiteley Ave., Novokuznetsk, 654005

ФГБОУ ВО Алтайский государственный медицинский университет; КГБУЗ Алтайская краевая офтальмологическая больницаРоссияAltai State Medical University; Altai Regional Ophthalmological HospitalRussian FederationФГБОУ ВО Алтайский государственный медицинский университетРоссияAltai State Medical UniversityRussian FederationНовокузнецкий государственный институт усовершенствования врачей — филиал ФГБОУ ДПО РМАНПО МЗ РФРоссияNovokuznetsk State Institute of Advanced Doctor Training — branch of Russian Medical Academy of Continuous Professional EducationRussian Federation2022010620222128492Copyright © Макогон С.И., Иванова Д.И., Онищенко А.Л., 20222022Макогон С.И., Иванова Д.И., Онищенко А.Л.Makogon I.S., Ivanova D.I., Onishchenko A.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.glaucomajournal.ru/jour/article/view/388

В настоящее время глаукома занимает первое место среди причин необратимой слепоты и слабовидения. Стабилизации глаукомного процесса, особенно на начальных стадиях, можно добиться путем воздействия на доказанный фактор риска — уровень внутриглазного давления — с помощью медикаментозного лечения. Учитывая пожилой и старческий возраст пациентов с глаукомой и наличие коморбидной соматической патологии, где лидирующие позиции занимают заболевания сердечно-сосудистой системы, актуальными становятся вопросы взаимодействия местной и системной терапии. В обзоре представлена роль β-адреноблокаторов, которые часто назначают и офтальмологи, и врачи терапевтического профиля, особенности их использования и взаимодействия, снижение внутриглазного давления при их системном применении, биодоступность, возможные нежелательные побочные эффекты в результате совместного использования. Повышение осведомленности офтальмологов, кардиологов, терапевтов и врачей общей практики о потенциальной проблеме совместного назначения должно стимулировать более тщательный подход к сбору анамнеза у пациентов, которым назначают местные и системные β-адреноблокаторы.

Glaucoma currently ranks first among the causes of irreversible blindness and low vision. Stabilization of the glaucomatous process, especially at its initial stages, can be achieved by using drug therapy to affect the proven risk factor — the level of intraocular pressure. Taking into account the elderly and senile age of patients with glaucoma and the presence of comorbid somatic pathologies, most common being cardiovascular system diseases, the issues of interaction between local and systemic therapy in this group of patients become especially relevant. This article reviews the role of β-blockers, which are often prescribed by both ophthalmologists and therapeutic specialists, the features of their use and interaction, the decrease in intraocular pressure provided by systemic therapy, their bioavailability, and the possible undesirable side effects as a result of mixed delivery. Raising the awareness among ophthalmologists, cardiologists and general practitioners on the potential problems of co-prescribing should encourage more careful approach to reviewing patients’ history of previously prescribed topical and systemic β-blockers.

глаукомазаболевания сердечнососудистой системыместное и системное применение β-адреноблокаторовпобочные эффектыglaucomadiseases of the cardiovascular systemlocal and systemic use of β-blockersside effectsавторы не получали финансирование при проведении исследования и написании статьиthe authors received no specific funding for this workReferencesЕгоров Е.А., Еричев В.П., Онищенко А.Л., Петров С.Ю. и др. Системные факторы риска развития первичной открытоугольной глаукомы. РМЖ Клиническая офтальмология 2018; 18(3):140-145. https://doi.org/10.21689/2311-7729-2018-18-3-140-145Egorov E.A., Erichev V.P., Onishchenko A.L., Petrov S.Yu. et al. Systemic risk factors for the development of primary open-angle glaucoma. Breast cancer. RMJ Clinical Ophthalmology 2018; 18(3):140-145. (In Russ.) https://doi.org/10.21689/2311-7729-2018-18-3-140-145Grzybowski A., Och M., Kanclerz P., Leffler C. et al. Primary open angle glaucoma and vascular risk factors: a review of population based studies from 1990 to 2019. Journal of Clinical Medicine 2020; 9(3):761. https://doi.org/10.3390/jcm9030761Grzybowski A., Och M., Kanclerz P., Leffler C. et al. Primary open angle glaucoma and vascular risk factors: a review of population based studies from 1990 to 2019. Journal of Clinical Medicine 2020; 9(3):761. https://doi.org/10.3390/jcm9030761Алексеев В.Н., Запорожец Л.А., Ал-Майсам Р. Первичная глаукома у больных с различной соматической патологией: особенности наблюдения и течения. РМЖ Клиническая офтальмология 2016; 2:79-82. https://doi.org/10.21689/2311-7729-2016-16-2-79-82.Alekseev V.N., Zaporozhets L.A., Al-Maisam R. Primary glaucoma in patients with various somatic pathologies: features of observation and course. RMJ Clinical Ophthalmology 2016; 2:79-82. (In Russ.) https://doi.org/10.21689/2311-7729-2016-16-2-79-82.Wändell P., Carlsson A.C., Ljunggren G. Systemic diseases and their association with open-angle glaucoma in the population of Stockholm. Int Ophthalmol 2021. https://doi.org/10.1007/s10792-021-02137-wWändell P., Carlsson A.C., Ljunggren G. Systemic diseases and their association with open-angle glaucoma in the population of Stockholm. Int Ophthalmol 2021. https://doi.org/10.1007/s10792-021-02137-wМакогон С.И., Макогон А.С. Исследование коморбидности у пациентов разных возрастных групп c первичной открытоугольной глаукомой. Национальный журнал глаукома 2017; 16(1):5-14.Makogon S.I., Makogon A.S. Study of comorbidity in patients of different age groups with primary open-angle glaucoma. Natsional'nyj zhurnal glaukoma 2017; 16(1):5-14. (In Russ.)Langman M.J.S., Lancashire R.J., Cheng K.K., Stewart P.M. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol 2005; 89(8):960-963. https://doi.org/10.1136/bjo.2004.053397Langman M.J.S., Lancashire R.J., Cheng K.K., Stewart P.M. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol 2005; 89(8):960-963. https://doi.org/10.1136/bjo.2004.053397Horwitz A., Klemp M., Jeppesen J., Tsai J. et al. Antihypertensive medication postpones the onset of glaucoma: evidence from a nationwide study. Hypertension 2017; 69(2):202-210, https://doi.org/10.1161/HYPERTENSIONAHA.116.08068Horwitz A., Klemp M., Jeppesen J., Tsai J. et al. Antihypertensive medication postpones the onset of glaucoma: evidence from a nationwide study. Hypertension 2017; 69(2):202-210, https://doi.org/10.1161/HYPERTENSIONAHA.116.08068De Moraes C.G, Cioffi G.A., Weinreb R.N., Liebmannet J.M. New recommendations for the treatment of systemic hypertension and their potential implications for glaucoma management. J Glaucoma 2018; 27(7):567-571. https://doi.org/10.1097/IJG.0000000000000981De Moraes C.G, Cioffi G.A., Weinreb R.N., Liebmannet J.M. New recommendations for the treatment of systemic hypertension and their potential implications for glaucoma management. J Glaucoma 2018; 27(7):567-571. https://doi.org/10.1097/IJG.0000000000000981He Z., Vingrys A.J., Armitage J.A., Bui B.V. The role of blood pressure in glaucoma. Clin Exp Optom 2011; 94(2):133-149. https://doi.org/10.1111/j.1444-0938.2010.00564.xHe Z., Vingrys A.J., Armitage J.A., Bui B.V. The role of blood pressure in glaucoma. Clin Exp Optom 2011; 94(2):133-149. https://doi.org/10.1111/j.1444-0938.2010.00564.xKlein B.E.K., Klein R., Knudtson M.D. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol 2005; 89(3):284-287. https://doi.org/10.1136/bjo.2004.048710Klein B.E.K., Klein R., Knudtson M.D. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol 2005; 89(3):284-287. https://doi.org/10.1136/bjo.2004.048710Bonomi L., Marchini G., Marraffa M., Bernardi Р. et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000; 107(7):1287-1293. https://doi.org/10.1016/s0161-6420(00)00138-xBonomi L., Marchini G., Marraffa M., Bernardi Р. et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000; 107(7):1287-1293. https://doi.org/10.1016/s0161-6420(00)00138-xMitchell P., Lee A.J., Rochtchina E., Bernardi P. et al. Open-angle glaucoma and systemic hypertension: the blue mountains eye study. J Glaucoma 2004; 13(4):319-326. https://doi.org/10.1016/s0161-6420(00)00138-xMitchell P., Lee A.J., Rochtchina E., Bernardi P. et al. Open-angle glaucoma and systemic hypertension: the blue mountains eye study. J Glaucoma 2004; 13(4):319-326. https://doi.org/10.1016/s0161-6420(00)00138-xMelgarejo JD, Lee JH, Petitto M, Yépez J.B. et al. Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo aging study. Ophthalmology 2018; 125(6):807-814. https://doi.org/10.1016/j.ophtha.2017.11.029Melgarejo JD, Lee JH, Petitto M, Yépez J.B. et al. Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo aging study. Ophthalmology 2018; 125(6):807-814. https://doi.org/10.1016/j.ophtha.2017.11.029Topper J.E., Brubaker R.F. Effects of timolol, epinephrine and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 1985; 26(10):1315-1319.Topper J.E., Brubaker R.F. Effects of timolol, epinephrine and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 1985; 26(10):1315-1319.Reiss G.R., Lee D.A., Torrer J.E. Brubaker R.F. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci 1984; 25(6):776-778.Reiss G.R., Lee D.A., Torrer J.E. Brubaker R.F. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci 1984; 25(6):776-778.Maus T.L., Mclaren J.W., Sherard J.W.Jr., Brubaker R.F. The effects of sleep on circulating catecholamines and aqueous flow in human subjects. Exp Eye Res 1996; 62(4):351-358. https://doi.org/10.1006/exer.1996.0040.Maus T.L., Mclaren J.W., Sherard J.W.Jr., Brubaker R.F. The effects of sleep on circulating catecholamines and aqueous flow in human subjects. Exp Eye Res 1996; 62(4):351-358. https://doi.org/10.1006/exer.1996.0040.Katz I.M., Berger E.T. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol 1979; 23(6):395-398. https://doi.org/10.1016/0039-6257(79)90234-0Katz I.M., Berger E.T. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol 1979; 23(6):395-398. https://doi.org/10.1016/0039-6257(79)90234-0Schlecht L.P., Brubaker R.F. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmol 1988; 95(9):1212-1216. https://doi.org/10.1016/s0161-6420(88)33026-5Schlecht L.P., Brubaker R.F. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmol 1988; 95(9):1212-1216. https://doi.org/10.1016/s0161-6420(88)33026-5Boger W.P. Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol 1983; 28(Suppl):235-242. https://doi.org/10.1016/0039-6257(83)90138-8Boger W.P. Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol 1983; 28(Suppl):235-242. https://doi.org/10.1016/0039-6257(83)90138-8Steinert R.F., Thomas J.V. Boger W.P. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol 1981; 99(1):100-103. https://doi.org/10.1001/archopht.1981.03930010102012.Steinert R.F., Thomas J.V. Boger W.P. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol 1981; 99(1):100-103. https://doi.org/10.1001/archopht.1981.03930010102012.Еричев В.П. Проблемы длительной терапии глаукомы. Вестник офтальмологии. 2021; 137(5):354-360. https://doi.org/10.17116/oftalma2021137052354Erichev V.P. Problems of long-term therapy of glaucoma. Vestnik oftal'mologii. 2021; 137(5):354-360. (In Russ.) https://doi.org/10.17116/oftalma2021137052354Еричев В.П., Макарова А.С. Совместимость системных препаратов и местной гипотензивной терапии у пациентов с первичной открытоугольной глаукомой (аналитический обзор). Национальный журнал глаукома 2019; 18(2):93-101. https://doi.org/10.25700/NJG.2019.02.10Erichev V.P., Makarova A.S. Compatibility of systemic drugs and local antihypertensive therapy in patients with primary open-angle glaucoma (analytical review). Natsional'nyj zhurnal glaukoma 2019; 18(2):93-101. (In Russ). https://doi.org/10.25700/NJG.2019.02.10Kario K., Schwartz J.E., Pickering T.G. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alphaadrenergic blocker, doxazosin: results from the HALT Study. Hypertension 2000; 35(3):787-794. https://doi.org/10.1161/01.hyp.35.3.787Kario K., Schwartz J.E., Pickering T.G. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alphaadrenergic blocker, doxazosin: results from the HALT Study. Hypertension 2000; 35(3):787-794. https://doi.org/10.1161/01.hyp.35.3.787Kario K., Schwartz J.E., Davidson K.W., Pickering T.G. Gender differences in associations of diurnal blood pressure variation, awake physical activity and sleep quality with negative affect: the Work Site Blood Pressure Study. Hypertension 2001; 38(5):997-1002. https://doi.org/10.1161/hy1101.095009Kario K., Schwartz J.E., Davidson K.W., Pickering T.G. Gender differences in associations of diurnal blood pressure variation, awake physical activity and sleep quality with negative affect: the Work Site Blood Pressure Study. Hypertension 2001; 38(5):997-1002. https://doi.org/10.1161/hy1101.095009Sadiq S.A., Vernon S.A. Sublingual timolol — an alternative to topical medication in glaucoma? Br J Ophthalmol 1996; 80(6):532-535. https://doi.org/10.1136/bjo.80.6.532Sadiq S.A., Vernon S.A. Sublingual timolol — an alternative to topical medication in glaucoma? Br J Ophthalmol 1996; 80(6):532-535. https://doi.org/10.1136/bjo.80.6.532Letchinger S.L., Frohlichstein D., Glieser D.K., Higginbothamet E.J. al. Can the concentration of timolol or the frequency of its administration be reduced? Ophthalmology 1993; 100(8):1259-1262. https://doi.org/10.1016/s0161-6420(93)31496-xLetchinger S.L., Frohlichstein D., Glieser D.K., Higginbothamet E.J. al. Can the concentration of timolol or the frequency of its administration be reduced? Ophthalmology 1993; 100(8):1259-1262. https://doi.org/10.1016/s0161-6420(93)31496-xWandel T., Charap A.D., Lewis R.A., Partamianet L. et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986; 101(3):298-304. https://doi.org/10.1016/0002-9394(86)90823-8Wandel T., Charap A.D., Lewis R.A., Partamianet L. et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986; 101(3):298-304. https://doi.org/10.1016/0002-9394(86)90823-8Passo M.S., Palmer E.A., Van Buskirk E.M. Plasma timolol in glaucoma patients. Ophthalmology 1984; 91(11):1361-1363. https://doi.org/10.1016/s0161-6420(84)34141-0.Passo M.S., Palmer E.A., Van Buskirk E.M. Plasma timolol in glaucoma patients. Ophthalmology 1984; 91(11):1361-1363. https://doi.org/10.1016/s0161-6420(84)34141-0.Vuori M.L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233(3):131-134. https://doi.org/10.1007/BF00166604Vuori M.L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233(3):131-134. https://doi.org/10.1007/BF00166604Chatterjee S., Biondi-Zoccai G., Abbate A., D'Ascenzo F. et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013; 346:f55. https://doi.org/10.1136/bmj.f55Chatterjee S., Biondi-Zoccai G., Abbate A., D'Ascenzo F. et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013; 346:f55. https://doi.org/10.1136/bmj.f55Yancy C.W., Jessup M., Bozkurt B., Javed Butler J. et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):e240-327. https://doi.org/10.1161/CIR.0b013e31829e8776Yancy C.W., Jessup M., Bozkurt B., Javed Butler J. et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):e240-327. https://doi.org/10.1161/CIR.0b013e31829e8776Rosendorff C., Lackland D.T., Allison M., Wilbert S., Aronow W.S. et al. Treatment of hypertension in patients with coronary artery disease. A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension 2015; 65(6):1372-1407. https://doi.org/10.1161/HYP.0000000000000018Rosendorff C., Lackland D.T., Allison M., Wilbert S., Aronow W.S. et al.Treatment of hypertension in patients with coronary artery disease. A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension 2015; 65(6):1372-1407. https://doi.org/10.1161/HYP.0000000000000018Montalescot G., Sechtem U., Achenbach S., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38):2949-3003. https://doi.org/10.1093/eurheartj/eht296Montalescot G., Sechtem U., Achenbach S., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38):2949-3003. https://doi.org/10.1093/eurheartj/eht296Huang H.L., Fox K.A. The impact of beta-blockers on mortality instable angina: a meta-analysis. Scott Med J 2012; 57(2):69-75. https://doi.org/10.1258/smj.2011.011274Huang H.L., Fox K.A. The impact of beta-blockers on mortality instable angina: a meta-analysis. Scott Med J 2012; 57(2):69-75. https://doi.org/10.1258/smj.2011.011274Артериальная гипертензия у взрослых. Клинические рекомендации. Российское кардиологическое общество 2020; 136.Артериальная гипертензия у взрослых. Клинические рекомендации. Российское кардиологическое общество 2020; 136.Khawaja A.P., Chan M.P.Y., Broadway D.C., Garway-Heath D.F. et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology 2014; 121(8):1501-1507. https://doi.org/10.1016/j.ophtha.2014.02.009Khawaja A.P., Chan M.P.Y., Broadway D.C., Garway-Heath D.F. et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology 2014; 121(8):1501-1507. https://doi.org/10.1016/j.ophtha.2014.02.009Williamson J., Young J.D., Atta H., Muir G., et al. Comparative efficacy of orally and topically administered I blockers for chronic simple glaucoma. British Journal of Ophthalmology 1985; 69(1):41-45. https://doi.org/10.1136/bjo.69.1.41Williamson J., Young J.D., Atta H., Muir G., et al. Comparative efficacy of orally and topically administered I blockers for chronic simple glaucoma. British Journal of Ophthalmology 1985; 69(1):41-45. https://doi.org/10.1136/bjo.69.1.41De Voogd S., Ikram M.K., Wolfs R.C., Jansonius N.M. et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005; 112(9):1487-1493. https://doi.org/10.1016/j.ophtha.2005.04.018De Voogd S., Ikram M.K., Wolfs R.C., Jansonius N.M. et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005; 112(9):1487-1493. https://doi.org/10.1016/j.ophtha.2005.04.018Wettrell K., Pandolfi M. Effect of Oral Administration of Various Betablocking Agents on the Intraocular Pressure in Healthy Volunteers. Eqx Eye Res 1975; 21(5):451-456. https://doi.org/10.1016/0014-4835(75)90126-8Wettrell K., Pandolfi M. Effect of Oral Administration of Various Betablocking Agents on the Intraocular Pressure in Healthy Volunteers. Eqx Eye Res 1975; 21(5):451-456. https://doi.org/10.1016/0014-4835(75)90126-8Tiong T.H., Hung S.O. Perelman M.S. Penetration of nadolol into aqueous humour after a single oral dose. Br J Clin Pharmac 1988; 26(1):92-95. https://doi.org/10.1111/j.1365-2125.1988.tb03369.xTiong T.H., Hung S.O. Perelman M.S. Penetration of nadolol into aqueous humour after a single oral dose. Br J Clin Pharmac 1988; 26(1):92-95. https://doi.org/10.1111/j.1365-2125.1988.tb03369.xFredric J.G., Schuman J.S. Reduced ocular hypotensive effect of topical beta blockers in glaucoma patients receiving oral beta blockers. J Glaucoma 1992; 1(3):174-177. https://doi.org/10.1097/00061198-199201030-00007Fredric J.G., Schuman J.S. Reduced ocular hypotensive effect of topical beta blockers in glaucoma patients receiving oral beta blockers. J Glaucoma 1992; 1(3):174-177. https://doi.org/10.1097/00061198-199201030-00007Schuman J.S. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 2000; 107(6):1171-1177. https://doi.org/10.1016/s0161-6420(00)00081-6Schuman J.S. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 2000; 107(6):1171-1177. https://doi.org/10.1016/s0161-6420(00)00081-6Goldberg I., Adena M.A. Co-prescribing of topical and systemic betablockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin Experiment Ophthalmol 2007; 35(8):700-705. https://doi.org/10.1111/j.1442-9071.2007.01573.xGoldberg I., Adena M.A. Co-prescribing of topical and systemic betablockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin Experiment Ophthalmol 2007; 35(8):700-705. https://doi.org/10.1111/j.1442-9071.2007.01573.xSommer A., Tielsch J.M., Katz J., Quigley H.A. et al. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991; 109(8):1090-1095. https://doi.org/10.1001/archopht.1991.01080080050026Sommer A., Tielsch J.M., Katz J., Quigley H.A. et al. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991; 109(8):1090-1095. https://doi.org/10.1001/archopht.1991.01080080050026Gherghel D., Orgül S., Gugleta K., Gekkieva M.et al. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol 2000; 130(5):597-605. https://doi.org/10.1016/S0002-9394(00)00766-2Gherghel D., Orgül S., Gugleta K., Gekkieva M.et al. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol 2000; 130(5):597-605. https://doi.org/10.1016/S0002-9394(00)00766-2Zheng Y., Wong T.Y., Mitchell P., Friedman D.S. et al. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the singapore malay eye study. Invest Ophthalmol Vis Sci 2010; 51(7):3399-3404. https://doi.org/10.1167/iovs.09-4867.Zheng Y., Wong T.Y., Mitchell P., Friedman D.S. et al. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the singapore malay eye study. Invest Ophthalmol Vis Sci 2010; 51(7):3399-3404. https://doi.org/10.1167/iovs.09-4867.Charlson M.E., de Moraes C.G., Link A., Wells M.T. et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. Ophthalmology 2014; 121(10):2004-2012. https://doi.org/10.1016/j.ophtha.2014.04.016Charlson M.E., de Moraes C.G., Link A., Wells M.T. et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. Ophthalmology 2014; 121(10):2004-2012. https://doi.org/10.1016/j.ophtha.2014.04.016Melgarejo J.D., Lee J.H., Petitto M., Juan B Yépez J.B. et al. Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo Aging Study. Ophthalmology 2018; 125(6):807-814. https://doi.org/10.1016/j.ophtha.2017.11.029.Melgarejo J.D., Lee J.H., Petitto M., Juan B Yépez J.B. et al. Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo Aging Study. Ophthalmology 2018; 125(6):807-814. https://doi.org/10.1016/j.ophtha.2017.11.029.Pillunat K.R., Spoerl E., Jasper C., Furashova O. et al. Nocturnal blood pressure in primary open-angle glaucoma. Acta Ophthalmol 2015; 93(8):e621-e626. https://doi.org/10.1111/aos.12740Pillunat K.R., Spoerl E., Jasper C., Furashova O. et al. Nocturnal blood pressure in primary open-angle glaucoma. Acta Ophthalmol 2015; 93(8):e621-e626. https://doi.org/10.1111/aos.12740Krasińska B., Karolczak-Kulesza M., Krasiński Z., Pawlaczyk-Gabriel K. et al. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. Blood Press 2012; 21(4):240-248. https://doi.org/10.3109/08037051.2012.666423Krasińska B., Karolczak-Kulesza M., Krasiński Z., Pawlaczyk-Gabriel K. et al. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. Blood Press 2012; 21(4):240-248. https://doi.org/10.3109/08037051.2012.666423Kario K., Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004; 26(2):177-189. https://doi.org/10.1081/ceh-120028556Kario K., Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004; 26(2):177-189. https://doi.org/10.1081/ceh-120028556Nieminen T., Uusitalo H., Turjanmaa V., Bjärnhall G. et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005; 61(5-6):369-374. https://doi.org/10.1007/s00228-005-0945-2Nieminen T., Uusitalo H., Turjanmaa V., Bjärnhall G. et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005; 61(5-6):369-374. https://doi.org/10.1007/s00228-005-0945-2Korte, J.M., Kaila, T. Saari, M.K. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe's Arch Clin Exp Ophthalmol 2002; 240(6):430-435. https://doi.org/10.1007/s00417-002-0462-2Korte, J.M., Kaila, T. Saari, M.K. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe's Arch Clin Exp Ophthalmol 2002; 240(6):430-435. https://doi.org/10.1007/s00417-002-0462-2Vuori M.L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233(3):131-134. https://doi.org/10.1007/BF00166604Vuori M.L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233(3):131-134. https://doi.org/10.1007/BF00166604Vander Zanden J.А., Valuck R., Bunch C.L., Perlman J.I. et al. Systemic adverse effects of ophthalmic beta blockers. Ann Pharmacotherapy 2001; 35(12):1633-1637. https://doi.org/10.1345/aph.18464Vander Zanden J.А., Valuck R., Bunch C.L., Perlman J.I. et al. Systemic adverse effects of ophthalmic beta blockers. Ann Pharmacotherapy 2001; 35(12):1633-1637. https://doi.org/10.1345/aph.18464Сычев Д.А., Мошетова Л.К. Клинико-фармакологические аспекты сочетанной патологии: сердечно-сосудистые заболевания и глаукома. Национальный журнал глаукома. 2014; 13(2):99-104.Sychev D.A., Moshetova L.K. Clinical and pharmacological aspects of combined pathology: cardiovascular diseases and glaucoma. Natsional'nyj zhurnal glaukoma. 2014; 13(2):99-104. (In Russ.)Остроумова О.Д., Максимов М.Л. Безопасность применения бисопролола у больных с сочетанной патологией. Consilium medicum 2012; 1:64-66.Ostroumova O.D., Maksimov M.L. Safety of bisoprolol use in patients with combined pathology. Consilium medicum 2012; 1:64-66. (In Russ.)Calvo-Romero J., Lima-Rodriguez E. Bradycardia associated with ophthalmic beta-blockers. J Postgrad Med 2003; 49(2):186.Calvo-Romero J., Lima-Rodriguez E. Bradycardia associated with ophthalmic beta-blockers. J Postgrad Med 2003; 49(2):186.Sharifi M., Koch J., Steele R., Adler D. et al. Third degree AV block due to ophthalmic timolol solution. Int J Cardiol 2001; 80(2-3):257-259. https://doi.org/10.1016/s0167-5273(01)00489-2Sharifi M., Koch J., Steele R., Adler D. et al. Third degree AV block due to ophthalmic timolol solution. Int J Cardiol 2001; 80(2-3):257-259. https://doi.org/10.1016/s0167-5273(01)00489-2Филимонова Е.Э., Сорокин Е.Л., Коган М.П., Пашенцев Я.Е. Развитие системных аддитивных эффектов при приеме β-адреноблокаторов у пациентов с глаукомой на фоне хронических заболеваний. Вестник офтальмологии 2020; 136(6):155-164. https://doi.org/10.17116/oftalma2020136062155Filimonova E.E., Sorokin E.L., Kogan M.P., Pashentsev Ya.E. Development of systemic additive effects when taking β-blockers in patients with glaucoma on the background of chronic diseases. Vestnik oftal'mologii 2020; 136(6):155-164. (In Russ.) https://doi.org/10.17116/oftalma2020136062155Roughead E., Kalisch L., Pratt N., Killer G. et al. Managing Glaucoma in those with Co-morbidity: Not as Easy as it Seems. Ophthalmic Epidemiology 2012; 19(2):74-82. https://doi.org/10.3109/09286586.2011.638743Roughead E., Kalisch L., Pratt N., Killer G. et al. Managing Glaucoma in those with Co-morbidity: Not as Easy as it Seems. Ophthalmic Epidemiology 2012; 19(2):74-82. https://doi.org/10.3109/09286586.2011.638743Bannon J.A., Stewart K.A., DeLisser O., Schrogie J.J. Clinical experience with timolol maleate monotherapy of hypertension. Arch Intern Med 1986; 146(4):654-657.Bannon J.A., Stewart K.A., DeLisser O., Schrogie J.J. Clinical experience with timolol maleate monotherapy of hypertension. Arch Intern Med 1986; 146(4):654-657.Zimmerman T.J., Baumann J.D., Hetherington J. Side effects of timolol. Surv Ophthalmol 1983; 28(Suppl): 243-251. https://doi.org/10.1016/0039-6257(83)90140-6Zimmerman T.J., Baumann J.D., Hetherington J. Side effects of timolol. Surv Ophthalmol 1983; 28(Suppl): 243-251. https://doi.org/10.1016/0039-6257(83)90140-6Tavish N., Rasool N., Callahan, A.B., Stamper R.L. et al. (2017). Ophthalmic Timolol Hallucinations. Journal of Glaucoma 2017; 26(9): e214-e216. https://doi.org/10.1097/IJG.0000000000000712Tavish N., Rasool N., Callahan, A.B., Stamper R.L. et al. (2017). Ophthalmic Timolol Hallucinations. Journal of Glaucoma 2017; 26(9): e214-e216. https://doi.org/10.1097/IJG.0000000000000712Cimolai N. Neuropsychiatric adverse events from topical ophthalmic timolol. Clinical Medicine Research 2019; 17(3-4):90-96. https://doi.org/10.3121/cmr.2019.1486Cimolai N. Neuropsychiatric adverse events from topical ophthalmic timolol. Clinical Medicine Research 2019; 17(3-4):90-96. https://doi.org/10.3121/cmr.2019.1486Rana M.A., Mady A.F., Rehman B.A., Alharthy A., et al. From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient. Case Reports in Critical Care 2015; 2015:714919. https://doi.org/10.1155/2015/714919Rana M.A., Mady A.F., Rehman B.A., Alharthy A., et al. From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient. Case Reports in Critical Care 2015; 2015:714919. https://doi.org/10.1155/2015/714919Shore J.H., Fraunfelder F.T., Meyer S.M. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Psychopharmacol 1987; 7(4):264-267.Shore J.H., Fraunfelder F.T., Meyer S.M. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Psychopharmacol 1987; 7(4):264-267.Trawick A.B. Potential systemic and ocular side effects associated with topical administration of timolol maleate. J Am Optom Assoc 1985; 56(2):108-112.Trawick A.B. Potential systemic and ocular side effects associated with topical administration of timolol maleate. J Am Optom Assoc 1985; 56(2):108-112.Centre for Allied Health Evidence. Final report. Systematic literature review on the detection, diagnosis, management and prevention of glaucoma. Canberra, NHMRC, Department of Health and Ageing. 2009.Centre for Allied Health Evidence. Final report. Systematic literature review on the detection, diagnosis, management and prevention of glaucoma. Canberra, NHMRC, Department of Health and Ageing. 2009.Müskens R.P, de Voogd S., Wolfs R.C., Witteman J.C.M. et al. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmology 2007; 114(12):2221-2226. https://doi.org/10.1016/j.ophtha.2007.03.047Müskens R.P, de Voogd S., Wolfs R.C., Witteman J.C.M. et al. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmology 2007; 114(12):2221-2226. https://doi.org/10.1016/j.ophtha.2007.03.047Carroll S., Gaskin B., Goldberg I., Danesh-Meyer H. Glaucoma prescribing trends in Australia and New Zealand. Clin Exp Ophthalmol 2006; 34:213-218. https://doi.org/10.1111/j.1442-9071.2006.01196.xCarroll S., Gaskin B., Goldberg I., Danesh-Meyer H. Glaucoma prescribing trends in Australia and New Zealand. Clin Exp Ophthalmol 2006; 34:213-218. https://doi.org/10.1111/j.1442-9071.2006.01196.xGoldberg I., Moloney G., McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Med J Aust 2008; 189(7):356-357. https://doi.org/10.5694/j.1326-5377.2008.tb02077.xGoldberg I., Moloney G., McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Med J Aust 2008; 189(7):356-357. https://doi.org/10.5694/j.1326-5377.2008.tb02077.xValuck R., Perlman J., Anderson C., Wortman G. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf 2001; 10(6):511-516. https://doi.org/10.1002/pds.634Valuck R., Perlman J., Anderson C., Wortman G. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failureand depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf 2001; 10(6):511-516. https://doi.org/10.1002/pds.634Diamond J.P. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 1997; 11(5):352-360. https://doi.org/10.2165/00002512-199711050-00003Diamond J.P. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 1997; 11(5):352-360. https://doi.org/10.2165/00002512-199711050-00003Vuori M.L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233(3):131-134. https://doi.org/10.1007/BF00166604Vuori M.L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233(3):131-134. https://doi.org/10.1007/BF00166604Frishman W.H., Kowalski M., Nagnur S., Warshafsky S. et al. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on betaadrenergic blockade. Heart Dis 2001; 3(6):386-397. https://doi.org/10.1097/00132580-200111000-00007Frishman W.H., Kowalski M., Nagnur S., Warshafsky S. et al. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on betaadrenergic blockade. Heart Dis 2001; 3(6):386-397. https://doi.org/10.1097/00132580-200111000-00007Cox A. Systemic effects of ocular drugs. Adverse Drug React Bull 2002; 215:823-826.Cox A. Systemic effects of ocular drugs. Adverse Drug React Bull 2002; 215:823-826.Новикова В.В., Уткин С.И., Маршева Н.А., Сорокин Е.Л. и др. Оценка статуса пожилых пациентов до проведения офтальмохирургических операций. Геронтология и гериатрия: альманах 2001; 1:276-278.Novikova V.V., Utkin S.I., Marsheva N.A., Sorokin E.L. et al. Assessment of the status of elderly patients before ophthalmic surgery. Gerontologija i geriatrija: al'manakh 2001; 1:276-278. (In Russ.)

The authors declare that there are no conflicts of interest present.